To assess the novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943 in healthy subjects
Latest Information Update: 10 Aug 2021
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- 10 Aug 2021 New trial record
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association